Peptides vs. DSHEA: Why Most Peptides Can Never Be Supplements

What counts as a dietary ingredient under DSHEA?

DSHEA limits the dietary-ingredient definition to a closed list under 21 U.S.C. 321(ff)(1): a vitamin, a mineral, an herb or other botanical, an amino acid, a dietary substance used by man to supplement the diet by increasing total dietary intake, or a concentrate, metabolite, constituent, extract or combination of those categories. Nothing outside that list qualifies. A formulator cannot argue a novel synthetic molecule into the definition just because it behaves like a nutrient in the body.

Any product that meets the definition still carries obligations before it reaches shelf. Structure/function claims require the boldface disclaimer set out at 21 CFR 101.93 — 'This statement has not been evaluated by the Food and Drug Administration...' — plus a notice to FDA's Office of Dietary Supplement Programs within 30 days of first marketing. For the fuller walk-through of how DSHEA's supplement definition and approval myths interact, see Do Supplements Need FDA Approval? What DSHEA Really Says.

Why do synthetic peptides fail the dietary-ingredient definition?

Most synthetic peptides fail the first test before you even reach the drug question. BPC-157 is the clean example: it is not a vitamin, mineral, herb, amino acid in the statutory sense, or an extract of a food substance, so it does not fit any branch of 321(ff)(1). A lab-synthesized 15-amino-acid chain with no botanical or dietary-food origin simply has nowhere to sit on that list.

Labeling a product 'Research Use Only' does not change how FDA reads it. Under 21 CFR 201.128, intended use is the objective intent of whoever is legally responsible for the labeling, and that intent may be shown by labeling claims, advertising matter, oral or written statements, or by 'the circumstances surrounding the distribution of the article' — marketing context controls, not the disclaimer. FDA applied exactly this logic in its March 31, 2026 warning letter to Gram Peptides, finding that mechanism-of-action and weight-loss copy on the retatrutide and tirzepatide pages established drug intent despite RUO language.

The same letter shows how far this reaches. FDA held that selling bacteriostatic water alongside peptides requiring reconstitution independently proved human-use intent, because offering the two together demonstrates the water is meant for combination injection. Bundling reconstitution supplies is itself evidence against you.

What is the drug-preclusion clause and why does it block semaglutide?

The drug-preclusion clause at 21 U.S.C. 321(ff)(3)(B) removes from the supplement definition any article already approved as a new drug, or authorized for investigation as a new drug once substantial clinical investigations have been instituted and publicized — unless it was marketed as a food or supplement before that authorization existed. Semaglutide fails on both counts: FDA approved it as a drug years before anyone tried selling it as a supplement, so the exception that saves food-first ingredients never applies.

Here is the point most sellers get backwards: an unapproved peptide does not need FDA approval to be precluded. The clause also triggers once substantial clinical investigations are underway and made public, and Eli Lilly's retatrutide already clears that bar — its Phase 3 TRIUMPH program has published results, including roughly 28-30% average weight loss at 80 weeks on the 12 mg dose, with a marketing application expected around Q1 2027. That publication record, not a pending approval, is what closes the supplement door on retatrutide today.

FDA's own position matches this reading. The agency states plainly that retatrutide cannot be used in compounding under federal law because it is not a component of an approved drug and has not been found safe and effective for any condition, and it has already warned telehealth companies, API distributors and outsourcing facilities that sell or repackage it.

Are collagen peptides and creatine peptides an exception?

Yes, but only for peptides derived from food, not for lab-synthesized research peptides. Hydrolyzed collagen peptides and whey protein hydrolysates qualify as protein or amino-acid dietary substances under 21 U.S.C. 321(ff)(1)(D)-(F), and — this is treated as likely rather than definitively settled — they were marketed as foods or supplements long before any drug investigation touched them, so the preclusion clause in (ff)(3)(B) never reaches back to exclude them.

Creatine sits in the same lawful category: it is an amino-acid derivative with a decades-long food and supplement marketing history, not a peptide chain with a pending drug application shadowing it. The dividing line is not molecular complexity. It is which of the two statutory tests — dietary-ingredient fit, then preclusion — the specific molecule was marketed against first.

Can a 'GLP-1 gummy' legally contain any actual GLP-1 agonist?

No. Semaglutide and tirzepatide are both FDA-approved new drugs, which puts them squarely inside the 321(ff)(3)(B) preclusion clause regardless of what form they take. Putting either compound into a gummy, capsule or drop does not create a new legal category; it is still the sale of a prescription-only drug outside its approved channel.

A 'research use only' sticker does not fix this. FTC's guidance makes the same point from a different angle: in one compliance example, an acne-treatment app carried a disclaimer that it was 'for entertainment purposes only,' and FTC called the disclaimer directly contradictory and ineffective to negate the underlying treatment claim — the identical logic FDA used against Gram Peptides' RUO labeling.

Even a lawfully formulated weight-support gummy runs into ad-platform friction that has nothing to do with FDA. Weight-loss and dietary products face age-gating, clickbait restrictions and outright bans on certain claim types across every major platform, and the rules differ enough by network that operators should check the specifics before building a campaign, as covered in Can You Advertise Supplements on TikTok? 2026 Ad Rules.

What happens when FDA finds an undeclared peptide in a supplement?

FDA opens with the standard enforcement chain, not an on-the-spot seizure. It classifies the product as a drug under section 201(g)(1) if it is intended to treat, cure, mitigate or prevent disease or to affect body structure or function; as a 'new drug' under 201(p) because it lacks a general-safe-and-effective finding; and its sale as violating sections 301(d) and 505(a) — a chain that usually surfaces first in a warning letter.

The Gram Peptides letter of March 31, 2026 shows the pattern end to end. FDA cited mechanism-of-action and weight-loss language on the company's retatrutide and tirzepatide pages as intended-use evidence, then separately flagged bacteriostatic water sold alongside those peptides as further proof of human-injection intent. Two adjacent product listings, read together, built the case.

Naming the drug you resemble makes things worse, not better. Under 21 CFR 101.93(g)(2)(iv)(B), a supplement that references an ingredient well known to consumers for its use in preventing or treating a disease is treated as making an implied disease claim, which is exactly why 'for Ozempic users' or 'eases GLP-1 side effects' positioning converts a supplement into an unapproved drug on FDA's reading.

Which peptide-adjacent ingredients are lawful to formulate with?

A short list of peptide-adjacent ingredients survives both statutory tests, and each comes with its own compliance tail. Food-derived hydrolysates lead the list; the rest depend on route of administration and claim discipline.

None of this is permanent clearance. NMN's status could still be challenged in court after Loper Bright narrowed the deference courts once gave agency interpretations, and topical peptide cosmetics draw FDA warning letters routinely once claims drift from appearance to physiology. Treat every entry on this list as conditionally lawful, not permanently settled.

• Hydrolyzed collagen peptides and whey/casein protein hydrolysates — lawful dietary ingredients under 321(ff)(1)(D)-(F), with a marketing history that predates any drug investigation.
• Oral NMN — FDA reversed course in two September 29, 2025 letters, concluding beta-nicotinamide mononucleotide is not excluded under (ff)(3)(B); it still needs a New Dietary Ingredient notification, and self-affirmed GRAS status cannot substitute for one.
• Topical peptide cosmetics such as GHK-Cu — lawful as a cosmetic only while the claim stays at 'makes lines less noticeable by moisturizing'; claiming it increases collagen production converts the product into an unapproved drug.
• Injectable NAD+ — sits on FDA's 503A Category 1 bulk-substance list as a compounded drug under prescription control, a different regulatory track entirely from oral NMN or NR sold under DSHEA.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For educational pages, the supporting references should help readers verify search, crawlability, and public ad research context, especially Google helpful content guidance, Google SEO link best practices, and Meta Ad Library. Daily Intel then adds the direct-response interpretation layer so the page explains what the signal means for actual affiliate research decisions.

For deeper evaluation, continue through Nutra niche intelligence directory, Cholesterol Offers: The Statin-Adjacent Niche and Its Rules, Varicose Vein and Circulation Offers: Market and Claim Limits, Menopause and Women's Hormone Offers: Market and Rules, Fertility Offers: Two Buyers, High Emotion, and a Hard Claim Ceiling, and What is a VSL?. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.